Compare DexCom, Inc. (DXCM) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lowe`s Companies Inc — how do they compare? DexCom, Inc. trades at $90.47 (market cap $33.79B), while Lowe`s Companies Inc trades at $216.7 (market cap $124.06B). The key difference: Lowe`s Companies Inc is far larger — about 3.7× DexCom, Inc.'s market cap, and Lowe`s Companies Inc pays a 2.26% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LOW | |
|---|---|---|
Market Cap | $33.79B | $124.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $287.39 |
52-Week Low | $54.84 | $201.92 |
Enterprise Value | $33.24B | $165.81B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Lowe's (LOW) trades at $216.14, down 1.23% with a bullish technical outlook supported by moving averages. The company maintains solid fundamentals with consistent earnings beats and a 7.51% net margin, though revenue declined to $83.67B in 2025. Analyst consensus remains strongly positive with a $257.06 price target and 61% buy ratings. Recent news highlights upcoming Q2 2026 earnings and community investments.
LOW presents a compelling investment case with strong analyst support and stable cash flows, but faces risks from competitive pressures and declining revenue trends. The stock's current valuation at 18.7x P/E appears reasonable given earnings consistency, though investors should monitor same-store sales performance in the upcoming earnings report.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
